|
|||||
|
|
Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study |
|
| Authors: | Richard B. Lipton MD Joshua M. Cohen MD MPH FAHS Maja Galic PhD Michael J. Seminerio PhD Paul P. Yeung MD MPH DFAPA FAHS Ernesto Aycardi MD Marcelo E. Bigal MD PhD Kristen Bibeau PhD MSPH Dawn C. Buse PhD |
| Affiliation: | 1. Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA;2. Global Medical Affairs, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA;3. Global Medical Affairs, Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands;4. North America Medical Affairs, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA;5. Research and Development, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA |
| Abstract: | |
| Keywords: | chronic migraine depression fremanezumab headache impact quality of life |